Inclusion Criteria:

- Small-cell lung cancer.

- Patients who, after (at least) a first line of chemotherapy based on platinum, had a
partial response and then progressed, or who had a complete response and then
relapsed within three months following the last course of this first-line therapy.

- Measurable or assessable disease.

- Life expectancy >2 months.

- Patients with a therapeutic risk level of <5 points (see section 6: "Treatment
flowchart").

- Age >18 years;

- Performance status (WHO) <2;

- One measurable target lesion in a non irradiated region;

- Prior radiotherapy authorized unless it targeted the only measurable lesion;

- Biological criteria: WBC >2000/mm3, PMN >1500/mm3, platelets >100 000/mm3,
creatinemia <2 x ULN, bilirubinemia metastases)

- normal ECG

- written informed consent.

Exclusion Criteria:

- Non small-cell lung cancer.

- No objective response to platinum-based therapy

- Complete response lasting more than three months after the last course of first-line
treatment.

- Symptomatic brain metastases.

- Bone metastases, carcinomatous lymphangitis, ascites or pleurisy as sole assessable
disease manifestations.- Concurrent participation in another clinical trial.

- Therapeutic risk level of 6 points or more (see table)

- Uncontrolled clotting disorders;

- Uncontrolled severe infection;

- History of another malignancy, except for cervical carcinoma in situ or basocellular
cancer that are considered cured;

- Psychological, familial, sociological or geographic circumstances preventing
treatment follow-up as defined in the protocol;

- Patients deprived of their rights for administrative or legal reasons.